Aug 19, 2020 | Fraud Investigations, Government Investigations, White Collar Crime
Last week, the Criminal Division of the U.S. Department of Justice (DOJ) issued new guidance regarding enforcement of the Foreign Corrupt Practices Act (FCPA), wherein it addressed an inquiry by a United States investment advisor regarding its intent to pay a foreign...
Aug 13, 2020 | Fraud Investigations, Government Investigations, Health Care, White Collar Crime
On August 7, 2020, the U.S. Department of Justice (“DOJ”) announced the indictment of a psychiatrist and his office manager for allegedly importing and selling drugs not approved by the U.S. Food & Drug Administration (“FDA”). The DOJ alleges that for ten years,...
Aug 6, 2020 | COVID-19 Related Law, Fraud Investigations, Government Investigations, Health Care, Medicare and Medicaid
On August 4, 2020, the Office of Inspector General for the United States Department of Health and Human Services (OIG) updated its FAQs regarding the application of OIG’s administrative enforcement authorities to arrangements directly connected to the ongoing COVID-19...
Jul 21, 2020 | Fraud Investigations, Health Care
Since the beginning of the ongoing COVID-19 pandemic, the use of telemedicine and telehealth services has skyrocketed. In March, we wrote about the temporary expansion of telehealth services by the Center for Medicare and Medicaid Services (CMS). Specifically, CMS...
Jul 6, 2020 | False Claims Act, Fraud Investigations, Government Investigations, Health Care, Medicare and Medicaid
On June 26, 2020, the Eleventh Circuit Court of Appeals reinstated part of a $348 million verdict awarded pursuant to the False Claims Act (FCA). The court also held that a qui tam plaintiff may have standing to bring an FCA claim even after entering into a litigation...
Jul 2, 2020 | False Claims Act, Fraud Investigations, Government Investigations, Health Care, Medicare and Medicaid
On July 1, 2020, the U.S. Department of Justice (“DOJ”) announced two separate settlements with Novartis Pharmaceuticals Corporation (“Novartis”), totaling more than $729 million, involving allegations that Novartis paid kickbacks to doctors and patients. In the first...
